# Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer

> **NCT04997798** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer
- Estrogen Receptor Positive Tumor
- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Trastuzumab Pyrotinib Exemestane Dalpiciclib

## Key facts

- **NCT ID:** NCT04997798
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-01
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04997798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04997798, "Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04997798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*